Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Oxford’s Joint Research Office (JRO) has expanded to include teams from Oxford Health (OH) NHS Foundation Trust and Oxford Brookes University (OBU), joining the clinical research support teams from the University of Oxford (OU) and Oxford University Hospitals (OUH) NHS Foundation Trust.

Researcher working in lab, with a pipette. © University of Oxford/David Fisher

The Oxford JRO now includes both of Oxford’s NHS Foundation Trusts and both of its universities, promoting and facilitating greater collaborative working across and between the partner organisations in clinical research, for the benefit of the people they serve.

The development of the Oxford JRO has been supported at the highest level in each organisation and by the Board of the Oxford Academic Health Partners, of which all four institutions are members.

The JRO was originally established in 2011 to facilitate the delivery of clinical research in Oxford by improving communication and streamlining processes through shared knowledge and expertise between OU and OUH.

It featured in a recent Academy of Medical Sciences report which concluded that streamlining research through joint R&D offices was one of the key ways to enhance the interface between academia and the NHS to improve the health and wealth of the UK.

External shot of Boundary Brook House JRO Staff provide services such as research governance, contracts, grants, finance and business development. The combined efforts of the JRO’s teams have underpinned the success of the NIHR Oxford Biomedical Research Centre (BRC), and will now play a similar role with the NIHR Oxford Health BRC, the NIHR Oxford Health Clinical Research Facility (CRF) and the newly-established NIHR Oxford CRF.

The JRO has played a vital behind-the-scenes role in establishing Oxford’s leadership in healthcare research and its far-reaching benefits for patients, not just in the NHS, but also beyond the UK. This has been particularly evident since March 2020, with the JRO playing an important role in enabling Oxford researchers to develop the Oxford/AstraZeneca vaccine or identify treatments for COVID-19 in the RECOVERY Trial.

The research support teams from all four partner organisations will continue to operate autonomously, but they will work together to identify how they can align their processes and activities.

Oxford researchers, many of whom already deal with two or more of the partner organisations, will be asked to contribute to this process.

Image: Boundary Brook House in Oxford houses the Joint Research Office

 

 

 

Similar stories

The Nuffield Department of Women's & Reproductive Health's Clinical Research Group recruits its 2,000th participant to the Generation Study

Oxford’s Clinical Research Group (CRG) has reached an important milestone after recruiting its 2,000th participant to the nationwide Generation Study.

Dementias Platform UK (DPUK) blood biomarker project takes next step towards NHS dementia diagnosis

A project involving researchers from the Universities of Oxford and Cambridge, Imperial College London and Dementias Platform UK (DPUK) has been selected for a major UK initiative aimed at improving dementia diagnosis and helping more people access the support and treatment they need sooner.

Robotic hip and knee surgery fails to cut overall risk of repeat surgery

Two major studies from the University of Oxford, Queen Mary University of London and the University of Bristol, have found that robotic-assisted hip and knee replacement does not reduce the overall early risk of repeat surgery compared with conventional surgery.

Oxford medical student takes AI safety message to the Palace of Versailles

Oxford medical student Julian Shellard has presented at an international workshop on the future of Artificial Intelligence (AI) at the Palace of Versailles in Paris, highlighting the important role medical students can play in global conversations on shaping the future of science and medicine.

Everyday DNA damage reveals a hidden weakness in some cancers

Researchers in the Chapman Group at the MRC Weatherall Institute of Molecular Medicine, have discovered why cancer cells lacking a protein called ATM are particularly vulnerable to a class of cancer drugs known as PARP inhibitors, solving a scientific puzzle that has challenged researchers for nearly 20 years.

Dunn School publishes new children’s book to mark centenary

The collaboration with Oxford University Press brings the story of the development of Penicillin to a new audience